Atypical mechanism of NF-κB activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis
Open Access
- 14 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 31 (30), 3525-3535
- https://doi.org/10.1038/onc.2011.520
Abstract
The NF-κB transcription factor has a central role in diverse processes, including inflammation, proliferation and cell survival, and its activity is dysregulated in diseases such as autoimmunity and cancer. We recently identified the TRE17/ubiquitin-specific protease 6 (USP6) oncogene as the first de-ubiquitinating enzyme to activate NF-κB. TRE17/USP6 is translocated and overexpressed in aneurysmal bone cyst (ABC), a pediatric tumor characterized by extensive bone degradation and inflammatory recruitment. In the current study, we explore the mechanism by which TRE17 induces activation of NF-κB, and find that it activates the classical NF-κB pathway through an atypical mechanism that does not involve IκB degradation. TRE17 co-precipitates with IκB kinase (IKK), and IKK activity is augmented in stable cell lines overexpressing TRE17, in a USP-dependent manner. Optimal activation of NF-κB by TRE17 requires both catalytic subunits of IKK, distinguishing its mechanism from the classical and non-canonical pathways, which require either IKKβ or IKKα, respectively. TRE17 stimulates phosphorylation of p65 at serine 536, a modification that has been associated with enhanced transcriptional activity and nuclear retention. Induction of S536 phosphorylation by TRE17 requires both IKKα and IKKβ, as well as the IKKγ/NEMO regulatory subunit of IKK. We further demonstrate that TRE17(long) is highly tumorigenic when overexpressed in NIH3T3 fibroblasts, and that inhibition of NF-κB significantly attenuates tumor formation. In summary, these studies uncover an unexpected signaling mechanism for activation of classical NF-κB by TRE17. They further reveal a critical role for NF-κB in TRE17-mediated tumorigenesis, and suggest that NF-κB inhibitors may function as effective therapeutic agents in the treatment of ABC.Keywords
This publication has 49 references indexed in Scilit:
- Expanding role of ubiquitination in NF-κB signalingCell Research, 2010
- Deubiquitinases in the regulation of NF-κB signalingCell Research, 2010
- TRE17/Ubiquitin-specific Protease 6 (USP6) Oncogene Translocated in Aneurysmal Bone Cyst Blocks Osteoblastic Maturation via an Autocrine Mechanism Involving Bone Morphogenetic Protein DysregulationPublished by Elsevier BV ,2010
- TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-κBOncogene, 2010
- Rho Kinase-2 Activation in Human Endothelial Cells Drives Lysophosphatidic Acid-mediated Expression of Cell Adhesion Molecules via NF-κB p65Journal of Biological Chemistry, 2010
- MEKK3 is required for lysophosphatidic acid-induced NF-κB activationCellular Signalling, 2009
- Interleukin-1-induced NF-κB Activation Is NEMO-dependent but Does Not Require IKKβPublished by Elsevier BV ,2007
- Nuclear factor-κB in cancer development and progressionNature, 2006
- De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signallingNature, 2004
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999